Baylor College of Medicine: Substance-Related Disorders trials

The registry lists 17 Substance-Related Disorders studies with Baylor College of Medicine as lead sponsor. 1 are open to participants now and 1 have results posted.

Early Phase 1 1Phase 1 13Phase 2 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Functional Connectivity Alterations in Suicidal Patients Among Opioid UsersRecruitingNCT05489042Not applicable
• Carisbamate as a Potential Treatment for Alcohol DependenceCompletedNCT02435381Phase 1/2Results posted
• Expanding Reach of Evidence-based Psychotherapy for Veterans With Co-occurring Anxiety and Substance Use Disorders.CompletedNCT05372185Not applicable
• Entolimod, an Adjuvant for Vaccine AugmentationCompletedNCT03063736Early Phase 1
• DOX as a Potential Treatment for Methamphetamine DependenceCompletedNCT02785393Phase 1
• Pramipexole as a Treatment for Cocaine DependenceCompletedNCT01651377Phase 1
• A Pilot Study of Cabergoline for the Treatment of Cocaine DependenceCompletedNCT01651364Phase 1
• Exercise as a Behavioral Treatment for Cocaine DependenceCompletedNCT01601743Not applicable
• Modafinil - Escitalopram Study for Cocaine DependenceCompletedNCT01601730Phase 1
• RTI-336 as a Treatment for Methamphetamine DependenceWithdrawnNCT01601717Phase 1
• Varenicline as a Treatment for Methamphetamine DependenceCompletedNCT01571167Phase 1
• Rivastigmine as a Treatment for Methamphetamine DependenceCompletedNCT01073319Phase 1
• NAC as a Potential Treatment for Methamphetamine DependenceCompletedNCT01063205Phase 1
• The Effects of Doxazosin on the Cardiovascular and Subjective Effects of CocaineCompletedNCT01062945Phase 1
• An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine DependenceCompletedNCT01062451Phase 1
• Rivastigmine and Huperzine A as Treatments for Cocaine DependenceCompletedNCT01030692Phase 1
• Varenicline-Methamphetamine Interaction Study (2008)WithdrawnNCT00733967Phase 1